Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Biogen | Contract Pharma
Biogen Ends Trial of Its Drug for PSP - CurePSP
Medscape Neurology - After disappointing trial results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies. http://ms.spr.ly/6182Tn3Cq | Facebook
Biogen on Twitter: "Chris Henderson, VP, Neuromuscular and Movement Disorders Research Unit, highlights the importance of an early Progressive Supranuclear Palsy (PSP) diagnosis #PSPAwareness https://t.co/xDnZaZYYhT" / Twitter
Biogen Study - CurePSP
Biogen y Eisai aseguran que su fármaco lecanemab frena el deterioro cognitivo en el alzhéimer | Sociedad | EL PAÍS
Amanda Pereira Silva - Patient Services Analyst Pl - Biogen | LinkedIn
Acompañamos a... - Pharmexx Argentina part of Ashfield Group | Facebook
Biogen on Twitter: "We're dedicated to advancing research and development for movement disorders like progressive supranuclear palsy (#PSP). https://t.co/7NOueg0df4" / Twitter
Acerca de Biogen
AbbVie Discontinued a Drug Trial. Biogen Stock Is Falling. | Barron's
PSPH (Human) Recombinant Protein (Q01) - BIOGEN Científica
Biogen Stock Rebounds After Impressive Q3 Earnings | InvestorPlace
Biogen on Twitter: "We'll be showcasing our work in neuroscience including the areas of multiple sclerosis (#MS), spinal muscular atrophy (#SMA), Alzheimer's Disease (#AD) and progressive supranuclear palsy (#PSP) with poster and
FAQ on FDA Approval of Aducanumab - CurePSP
☑️Biogen México — Supplier from Mexico, experience with UNOPS — Health, Laboratory & Measurement, Research, Science & Innovation sectors — DevelopmentAid
Carla Erba - Latam PSP Lead - Biogen | LinkedIn
Corio PSP™ – Detox RejuveNation
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's | Fierce Biotech
Carla Erba - Latam PSP Lead - Biogen | LinkedIn
Biogen on Twitter: "Progressive Supranuclear Palsy (#PSP) Awareness Month may be over, but the work doesn't end here. #PSPAwareness https://t.co/oC0MNF0IVD" / Twitter
Programa de apoyo a pacientes (22/11/2022) – AEFI – Área Multimedia
Biogen looks to M&A to overcome competition to its MS franchise | Fierce Pharma
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Cure PSP - Can Progressive Supranuclear Palsy (PSP) be treated at all? The PASSPORT trial is investigating whether a new investigational study drug may slow the progression of PSP. Biogen plan to
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy | Biogen
